Regulation FD Disclosure, Management Change/Compensation (Form 8-K)

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On April 3, 2025, Kenneth Miller resigned his employment and position as Chief Commercial Officer of KORU Medical Systems, Inc. (the "Company"), effective immediately, to pursue a Chief Executive Officer role at an organization that does not compete with the Company. KORU Medical would like to thank Mr. Miller for his contributions to the Company and recognize the instrumental role he played in establishing and implementing strategic commercial growth priorities during his tenure.

Rob Cannon will lead the Company's commercial operations for the Core business until a succeeding Chief Commercial Officer is named. Mr. Cannon has served as the Company's Vice President of Sales for North America since November 2021 and has over 30 years of experience in sales across the healthcare industry, including11 years with McKesson, a healthcare supply chain management company specializing in providing pharmaceuticals and healthcare services across the globe, where he led the strategy, planning and implementation of sales, and marketing strategies focused on specialty pharma and home infusion channels.

The Company has retained the services of an executive search firm to commence the search for a new Chief Commercial Officer.

ITEM 7.01 REGULATION FD DISCLOSURE.

KORU Medical is reiterating full year 2025 revenue guidance of $38.0-$39.0 million, as issued on the Company's earnings call on March 12, 2025.

The information contained in this Item 7.01 is being furnished and shall not be deemed to be "filed" with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including statements regarding our financial guidance regarding full year 2025 results.